anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Danish people living at northern latitudes (56°N), often with overcast and foggy weather and few sunshine hours are at increased risk of vitamin D insufficiency. Although vitamin D is obtainable from fortified food and oily fish, the major source is the dermal synthesis of the vitamin D through exposure to solar ultraviolet light.

In the 19th century rickets was endemic in northern Europe, and many children developed rickets, a severe bone-deforming disease. Encouragement of sensible sun exposure, supplementation with cod liver oil and fortification of milk with vitamin D, resulted in an almost complete eradication of rickets by the end of the 19th century. At present vitamin D deficiency seems again to be more widespread. The classical outcomes of severe vitamin D deficiency are rickets in growing individuals and osteomalacia in adults. Low vitamin D status also relates to low bone density and increased risk of osteoporotic fractures. Although the incidence of rickets has declined over the last decades, cases attributable to inadequate vitamin D intake and low exposure to sunlight continue to be reported, and maternal vitamin D status may have permanent effects on newborns' health. Pregnant women, newborns, breastfed children, and lactating women are at a high risk of vitamin D deficiency, especially during winter and early spring.

Since fetal plasma 25-hydroxyvitamin D (25OHD) depends on maternal 25OHD, fetal vitamin D status may show seasonal changes parallel to those observed in the mothers. To prevent rickets and vitamin D deficiency in infants, most Western countries, including Denmark, recommend a daily maternal intake during pregnancy and lactation of 10 μg and that breastfed children are given a supplement of 10 μg of vitamin D/day. Despite these recommendations, approximately one third of Danish pregnant and lactating women have vitamin D insufficiency. However, childhood rickets is nowadays rare in Denmark, although it still exists especially among immigrants and mothers with prolonged lactation. Accordingly, in 2010, the Danish National Board of Health extended the recommendations for vitamin D supplementation to the first two years of life.
Objective: To investigate the clinicopathological characteristics of giant cell tumor of bone (GCTB) in children. Methods: A total of 35 cases of GCTB diagnosed at Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University School from 2016 to 2023 were collected, and a retrospective analysis of clinicopathological features and imaging findings was conducted. Results: Pediatric GCTB accounted for approximately 4.6% of total GCTB cases during the study period. There were 11 males and 24 females. The onset age ranged from 9 to 18 years (mean age 15 years, median age 16 years), with 8 cases (8/35, 22.9%) experiencing postoperative recurrence. Twenty-eight cases (28/35, 80%) primarily affected long bones, while 7 cases involved small or irregular bones. Imaging revealed osteolytic changes as the predominant feature, with 3 cases exhibited open physis, one of which had the tumor primarily at the diaphysis without crossing the physis. Histologically, pediatric GCTB resembled adult cases, characterized by mononuclear cells and osteoclast-like giant cells. Seven cases with denosumab treatment demonstrated degrees of giant cell disappearance, increased fibrous tissue and reactive bone proliferation in the stroma. One case was diagnosed as pediatric multicentric GCTB, and three cases as pediatric primary malignant GCTB, with malignant transformation into osteosarcoma. In all 35 cases, mutations in the H3F3A gene were identified, comprising 32 cases with H3.3 p.G34W mutations, one case with H3.3 p.G34V mutation, and 2 cases with H3.3 p.G34L mutations. Notably, the former two categories were successfully validated at the protein level through immunohistochemical staining, utilizing highly specific antibodies tailored for these mutation types: H3.3 p.G34W antibody and H3.3 p.G34V antibody. However, immunohistochemical staining was not available for the last category. Conclusions: Pediatric GCTB predominantly affects females and occurs primarily in long bones, mainly around the knee joint, the majority of tumors predominantly arise in the epiphysis and extend into the metaphysis; however, in cases where the epiphyseal plates are still unclosed, the tumors may be restricted to the metaphysis. Detection of H3F3A gene mutation is crucial for the diagnosis and differential diagnosis of pediatric GCTB.
GCS was the total scores of all six land-marks, ranging from 6 (completely unprepared) to 24 (perfect). We define that GCS \< 18 is inadequate.
The patient will start to administer: (1) daily subcutaneous injections of gonadotropins on day 1 of ovarian stimulation (2) daily subcutenous injections of ganirelix ("antagonist") on day 5 or 6 of ovarian stimulation. Both medication will be stopped 1-2 days before egg retrieval.
NEW MATERIAL:A lactam compound, containing sulfur or selenium, and expressed by formulaI(A is amino, etc.; COB is carboxy, etc.; Q is S or Se; R is alkyl, etc. which may have a substituent group; W is H or nucleophilic group; X is H, methoxyl, etc.; Y is O, S or -SO-; n is 0, 1 or 2). EXAMPLE:Diphenylmethyl 7beta-(2-thiopheneacetamido)-7alpha-methoxy-3beta-phenylthio3alpha-ace toxymethyl-1-dethia-1-oxacephem-4alpha-carboxylate expressed by formula II. USE:A synthetic raw material for cephalosporin beta-lactam compounds. PROCESS:A sulfinyl halide or selenyl halide is added to an oxomethylene compound expressed by formula III to give a compound expressed by formula IV, which is then reacted with a nucleophilic reagent, eg.g a tertiary amine, to afford a compound. The functional group of the resultant compound is then exchanged to give a compound expressed by formula V (n is 0) which is then oxidized to afford a monoxide expressed by formula VI (n is 1) or a dioxide expressed by formula VII (n is 2).
Participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
Provided are: a receiving container capable of achieving, by a simple member, the protection of a microneedle array before tapping, and the tapping properties of the microneedle array; a microneedle unit; a receiving container group; and a method for producing a microneedle unit. The receiving container receives a microneedle array including: a sheet unit which has first and second surfaces facing each other; and a plurality of needle units which are disposed on the first surface of the sheet unit. The receiving container comprises: a first member having an edge part dividedly forming a second opening; and a second member having a concave part. The receiving container receives a microneedle array by making the second member overlap the first member. In a state in which the second member overlaps the first member, power is applied to the second member, and thus the first member and the second member are transformed. Also, a needle unit of the microneedle array is made to protrude from the first member, and tapping is performed on skin.
Group 2 will be recruited from the Neurology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) and neuropathy. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
PURPOSE: To obtain the subject therapeutic agent useful for treating/preventing placental and/or fetal abnormal diseases, having improving action on placental and fetal disorder and aplasia, containing a hepatocyte growth factor as an active ingredient. CONSTITUTION: This therapeutic agent comprises a hepatocyte growth factor (hereinafter abbreviated to HCG) as an active ingredient. HGF has the following physical and chemical characteristics. Estimated molecular weight by SDS-PAGE (under nonreducing conditions): about 76,000-92,000. Having activity to multiply a hepatocyte. The activity is deactivated by heat treatment at 80 deg.C for 10 minutes. Having high affinity for heparin. Bonding to CM-cellulose equilibrated with 10 mM phosphoric acid solution (pH 7.0). No reduction in activity by treatment with 1N acetic acid at room temperature for 12 hours. No reduction in activity in treatment with 1% formic acid at 4 deg.C for 12 hours. Also no reduction in activity in heat treatment at 55 deg.C for 30 minutes.
FIELD: medicine, pharmacology. SUBSTANCE: method involves the dissolving substances showing capability to form lipid vesicules in organic solvent, drying solution prepared with lipid film formation, resuspending lipid film in dispersed medium and dispersing suspended lipids into microemulsion by suspension passing through the microgap at pressure gradient. Pressure gradient is 50-300 atm of normal value. Dispersion medium: drug aqueous solution, for example, cytostatic, immunomodulating agent and others. Substances that are able to form lipid vesicules: mixture of lecithin and acid phospholipids isolated from soybean phosphatides. EFFECT: preparing lipisomes at particle size diameter , low degree of lipid peroxidation.
Screening methods are provided for identifying pharmacologic inhibitors of HCV amphipathic helix (AH) function, which inhibitors are useful in the prevention and treatment of HCV infection. Also provided are compounds useful in the inhibition of viral replication. The methods of the invention are based on the unexpected discovery that the presence of an AH, e.g. an AH of an HCV polypeptide, causes an increase in the apparent diameter of the vesicles. The methods of the invention provide for addition of AH peptides to lipid vesicles, for example in a high-throughput format; which addition may be performed in the absence or presence of a candidate pharmacologic agent. The change in apparent vesicle size is measured, and compared to control samples. An increase in vesicle size or aggregation is indicative of AH function being present; and a lack of increase is indicative that the AH function is absent or has been inhibited by a test agent.
Placebo surgery. This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. Investigators do not perform removal of the corneal epithelium in edge of the ulcer. The researchers conducted "the impregnation phase" applying drops of saline solution for 10 minutes. After impregnation fase, a device is placed in Avedro equipment off (Avedro Inc, Waltham, USA) this device emits white light for 3 minutes. After procedure, conventional treatment for keratitis remains unchanged.
BACKGROUND: Chronic kidney disease (CKD) is a growing global health concern. Identifying individuals in routine clinical care with new-onset CKD at high risk of rapid progression of the disease is imperative to guide allocation of prophylactic interventions, but community-based data are limited. We aimed to examine the risk of rapid progression, kidney failure, hospitalization and death among adults with incident CKD stage G3 and to clarify the association between predefined risk markers and rapid CKD progression.
METHODS: Using plasma creatinine measurements for the entire Danish population from both hospitals and primary care, we conducted a nationwide, population-based cohort study, including adults in Denmark with incident CKD stage G3 in 2017-2020. We estimated 3-year risks of rapid progression (defined by a confirmed decline in estimated glomerular filtration rate of ≥5 mL/min/1.73 m2/year), kidney failure, all-cause hospitalization and death. To examine risk markers, we constructed a heat map showing the risk of rapid progression based on predefined markers: albuminuria, sex, diabetes and hypertension/cardiovascular disease.
RESULTS: Among 133 443 individuals with incident CKD stage G3, the 3-year risk of rapid progression was 14.6% [95% confidence interval (CI) 14.4-14.8]. The 3-year risks of kidney failure, hospitalization and death were 0.3% (95% CI 0.3-0.4), 53.3% (95% CI 53.0-53.6) and 18.1% (95% CI 17.9-18.4), respectively. In the heat map, the 3-year risk of rapid progression ranged from 7% in females without albuminuria, hypertension/cardiovascular disease or diabetes, to 46%-47% in males and females with severe albuminuria, diabetes and hypertension/cardiovascular disease.
CONCLUSION: This population-based study shows that CKD stage G3 is associated with considerable morbidity in a community-based setting and underscores the need for optimized prophylactic interventions among such patients. Moreover, our data highlight the potential of using easily accessible markers in routine clinical care to identify individuals who are at high risk of rapid progression.
Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The present invention is to formulate a powder intranasal administrating preparation comprising particulate steroid hormones with an average particle size of 50~300 [mu]m as active ingredient. The above powder intranasal administrating preparation may further comprise water-soluble polymer (especially, water-soluble saccharides such as cellulose having hydroxyalkyl groups). The above particulate steroid hormones may be formed as testosterone and/or derivatives thereof. The above water-soluble polymer may be particulate. The ratio of the above water-soluble polymer is about 1~50 parts by weight to the above particulate steroid hormones 1 part by weight. The above powder intranasal administrating preparation may be a powder intranasal administrating preparation capable of adjusting the Cmax of the steroid hormones lower than 15 ng/ml. Provided is a powder intranasal administrating preparation capable of controlling the blood concentration of the steroid hormones such as testosterone within a specific range during a long period.
A nose bleed treatment system for use in treating a patient having a nose bleed uses a nose clip that has a swab adjustment holder disposed on it to moveably hold a bulky or oversized swab within it. The swab can be moved to press against a bleed site in a patient having a bloody nose. A medically effective agent is applied to the bleed site either by applying it to the swap or by using a specially designed spray bottle. In the embodiment using the spray bottle, the bottle has an elongated tip that allows the user to position the tip of the spray bottle proximal to the bleed site. The medically effective agent contains at least one of a clot enhancing agent and a vasoconstricting agent. The agent may contain vitamin K as well as a vasoconstricting agent epinephrine.
The invention provides an automated hand hygiene/infection control monitoring sensor-based system suitable for improving hand hygiene and multiple infection control measures and ensuring compliance by health care workers as well as visitors to hospitals and clinics. The use of biometric identification devices such as cameras for face recognition and profiling, microphones for voice recognition, etc. permit highly accurate identification without the use of removable identification devices such as identification badges which may include bar codes, magnetic strips or wireless devices such as RFIDS. Identification badges are removable and hence susceptible to being lost, misplaced, etc. Visitors are typically not assigned identification badges and hence enforcement of hand hygiene policies is minimal. Additional applications include reducing food contamination in food industry, the spread of diseases in schools, in businesses, in corporations and governmental facilities and public access facilities such as public restrooms, dining areas and transportation.
Physical dependence is the occurrence of withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an opioid antagonist or mixed opioid agonist/antagonist agent. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). The development of physical dependence and tolerance is not unusual during chronic opioid therapy.

If OPANA ER is abruptly discontinued in a physically-dependent patient, an abstinence syndrome may occur. Some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.

In general, OPANA ER should not be abruptly discontinued. However, OPANA ER, like other opioids, can be safely discontinued without the development of withdrawal symptoms by slowly tapering the daily dose (see DOSAGE AND ADMINISTRATION: Cessation of Therapy).
FIELD: cardiology. SUBSTANCE: minced animal hearts were treated twice with acetone and placed into reactor containing acetic acid. Then zinc chloride is added to the solution and after extraction termination substrate is centrifuged. Supernatant is decanted and stirred with acetone. Dried precipitate is milled, dissolved in water and filtered. Acetic acid is added to filtrate up to pH 4.5. Solution is filtered under sterile conditions, poured into flasks and lyophilized. The yield of an active substance is 0.127 kg. EFFECT: improved method of substance preparing. 1 tbl
Investigators applied vestibular rehabilitation in this group. This group was consist of 15 participants. After the evaluation investigators gave the patients repetitive vestibular exercises for 4 weeks and in the first week investigators performed canalith repositioning procedure depending on the affected canal. If affected posterior semicircular canal investigators applied Epley maneuver. If affected horizontal semicircular canal also applied barbeque roll maneuver.
The invention discloses a heat-resistant foot-and-mouth disease recombinant virus strain and application thereof in preparation of a foot-and-mouth disease inactivated vaccine. The heat-resistant foot-and-mouth disease recombinant virus strain is named as rM10 and is obtained by virus rescue of infectious cDNA shown in SEQ ID NO. 1. Experiments prove that the capsid of the recombinant virus strain is completely cracked at a higher temperature than that of the wild strain virus, which indicates that the foot-and-mouth disease recombinant virus strain rM10 obtained by rescue is more heat-resistant than the wild strain. The invention provides technical support for further promoting the research and application of the heat-stable vaccine and providing the prevention and control and thorough purification of major epidemic diseases. Meanwhile, the invention lays a foundation for preparing the stable foot-and-mouth disease vaccine.
Postoperative pain is a normal, physiologic, protective response to tissue injury that routinely resolves after healing of the surgical site. However, in some patients, pain persists long after surgery. PPSP is a diagnosis of exclusion that has most consistently been defined as pain that (1) developed after a surgical procedure, (2) is not residual from a preexisting condition, (3) has lasted for at least two months, and (4) is not attributable to other causes. One suggested risk factor for PPSP is poorer performance on tests of cognitive flexibility. Two common tests of cognitive flexibility are the Trail Making Tests (TMT) A and B and the Color Word Matching Stroop Test (CWMST).

Three hundred patients undergoing either total knee arthroplasty or thoracotomy/mastectomy will be enrolled. During preoperative evaluation, participants will complete the TMT and CWMST. Subjects will be followed prospectively and will complete surveys at one month, six months, and one year postoperatively to assess PPSP prevalence and intensity.
A catheter system including an elongate tubular member having a proximal end portion, a distal end portion and a lumen extending through at least a portion of a length of the elongate tubular member. The distal end portion of the elongate member is dimensioned and adapted to advance to or in proximity to a treatment site of a subject. A microbubble device is in fluid communication with the lumen. The microbubble device includes at least one input port for receiving a flow of material into the device and an output port configured to output microbubbles from the microbubble device. A second tubular member is in fluid communication with one of the at least one input ports. A pressure fitting arrangement is adapted to maintain a seal between the second tubular member and the input port.
Patients receive WSD0922-FU PO BID on C1D1 to C1D21 using dosage selected from Dose escalation. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and blood sample collection on study.
Both experimental and clinical liver fibrosis leave a metabolic footprint that can be uncovered and defined using metabolomic approaches. Metabolomics combines pattern recognition algorithms with analytical chemistry, in particular, 1H and 13C nuclear magnetic resonance spectroscopy (NMR), gas chromatography-mass spectrometry (GC-MS) and various liquid chromatography-mass spectrometry (LC-MS) platforms. The analysis of liver fibrosis by each of these methodologies is reviewed separately. Surprisingly, there was little general agreement between studies within each of these three groups and also between groups. The metabolomic footprint determined by NMR (two or more hits between studies) comprised elevated lactate, acetate, choline, 3-hydroxybutyrate, glucose, histidine, methionine, glutamine, phenylalanine, tyrosine and citrate. For GC-MS, succinate, fumarate, malate, ascorbate, glutamate, glycine, serine and, in agreement with NMR, glutamine, phenylalanine, tyrosine and citrate were delineated. For LC-MS, only β-muricholic acid, tryptophan, acylcarnitine, p-cresol, valine and, in agreement with NMR, phosphocholine were identified. The metabolomic footprint of liver fibrosis was upregulated as regards glutamine, phenylalanine, tyrosine, citrate and phosphocholine. Several investigators employed traditional Chinese medicine (TCM) treatments to reverse experimental liver fibrosis, and a commentary is given on the chemical constituents that may possess fibrolytic activity. It is proposed that molecular docking procedures using these TCM constituents may lead to novel therapies for liver fibrosis affecting at least one-in-twenty persons globally, for which there is currently no pharmaceutical cure. This in-depth review summarizes the relevant literature on metabolomics and its implications in addressing the clinical problem of liver fibrosis, cirrhosis and its sequelae.